Skip to main content

Advertisement

SpringerLink
Log in

Osteocalcin and the Regulation of Glucose Metabolism

  • Original Paper
  • Published:
Clinical Reviews in Bone and Mineral Metabolism Aims and scope Submit manuscript

Abstract

Uncarboxylated osteocalcin enhances insulin and adiponectin release and improves glucose tolerance in mice. Data in humans do not unequivocally support a role for osteocalcin in glucose homeostasis. Changes in the amount of uncarboxylated osteocalcin induced by vitamin K or warfarin treatment are not associated with changes in glucose and insulin concentrations. Interventional studies in humans, designed to detect small changes in insulin secretion and action attributable to changes in uncarboxylated osteocalcin, will be required to reliably detect effects of osteocalcin on glucose metabolism and to better understand its interaction with adiposity and adipokines.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Maury E, Brichard SM. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol. 2010;314:1–16.

    Article  PubMed  CAS  Google Scholar 

  2. Ducy P. The role of osteocalcin in the endocrine cross-talk between bone remodelling and energy metabolism. Diabetologia. 2011;54:1291–7.

    Article  PubMed  CAS  Google Scholar 

  3. Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med. 1998;338:736–46.

    Article  PubMed  CAS  Google Scholar 

  4. Reid IR. Relationships between fat and bone. Osteoporos Int. 2008;19:595–606.

    Article  PubMed  CAS  Google Scholar 

  5. Kawai M, Devlin MJ, Rosen CJ. Fat targets for skeletal health. Nat Rev Rheumatol. 2009;5:365–72.

    Article  PubMed  Google Scholar 

  6. Misra M, Klibanski A. Evaluation and treatment of low bone density in anorexia nervosa. Nutr Clin Care. 2002;5:298–308.

    Article  PubMed  Google Scholar 

  7. Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, Dacquin R, Mee PJ, McKee MD, Jung DY, Zhang Z, Kim JK, Mauvais-Jarvis F, Ducy P, Karsenty G. Endocrine regulation of energy metabolism by the skeleton. Cell. 2007;130:456–69.

    Article  PubMed  CAS  Google Scholar 

  8. Ferron M, Hinoi E, Karsenty G, Ducy P. Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci USA. 2008;105:5266–70.

    Article  PubMed  CAS  Google Scholar 

  9. Hauschka PV, Lian JB, Cole DE, Gundberg CM. Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. Physiol Rev. 1989;69:990–1047.

    PubMed  CAS  Google Scholar 

  10. Kumar R, Vella A. Carbohydrate Metabolism and the Skeleton: Picking a Bone with the {beta}-Cell. J Clin Endocrinol Metab. 2011;96:1269–71.

    Article  PubMed  CAS  Google Scholar 

  11. Dinneen S, Gerich J, Rizza R. Carbohydrate metabolism in non-insulin-dependent diabetes mellitus. N Engl J Med. 1992;327:707–13.

    Article  PubMed  CAS  Google Scholar 

  12. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329:977–986.

  13. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20:1183–1197.

    Google Scholar 

  14. Bock G, Dalla Man C, Campioni M, Chittilapilly E, Basu R, Toffolo G, Cobelli C, Rizza R. Pathogenesis of pre-diabetes: mechanisms of fasting and postprandial hyperglycemia in people with impaired fasting glucose and/or impaired glucose tolerance. Diabetes. 2006;55:3536–49.

    Article  PubMed  CAS  Google Scholar 

  15. Dinneen SF, Maldonado D III, Leibson CL, Klee GG, Li H, Melton LJ III, Rizza RA. Effects of changing diagnostic criteria on the risk of developing diabetes. Diabetes Care. 1998;21:1408–13.

    Article  PubMed  CAS  Google Scholar 

  16. Abdul-Ghani MA, Stern MP, Lyssenko V, Tuomi T, Groop L, Defronzo RA. Minimal contribution of fasting hyperglycemia to the incidence of type 2 diabetes in subjects with normal 2-h plasma glucose. Diabetes Care. 2010;33:557–61.

    Article  PubMed  CAS  Google Scholar 

  17. Basu A, Alzaid A, Dinneen S, Caumo A, Cobelli C, Rizza RA. Effects of a change in the pattern of insulin delivery on carbohydrate tolerance in diabetic and nondiabetic humans in the presence of differing degrees of insulin resistance. J Clin Invest. 1996;97:2351–61.

    Article  PubMed  CAS  Google Scholar 

  18. Caumo A, Luzi L. First-phase insulin secretion: does it exist in real life? Considerations on shape and function. Am J Physiol Endocrinol Metab. 2004;287:E371–85.

    Article  PubMed  CAS  Google Scholar 

  19. Sathananthan A, Man CD, Micheletto F, Zinsmeister AR, Camilleri M, Giesler PD, Laugen JM, Toffolo G, Rizza RA, Cobelli C, Vella A. Common genetic variation in GLP1R and insulin secretion in response to exogenous GLP-1 in nondiabetic subjects: a pilot study. Diabetes Care. 2010;33:2074–6.

    Article  PubMed  CAS  Google Scholar 

  20. Service FJ, Rizza RA, Zimmerman BR, Dyck PJ, O’Brien PC, Melton LJ III. The classification of diabetes by clinical and C-peptide criteria. A prospective population-based study. Diabetes Care. 1997;20:198–201.

    Article  PubMed  CAS  Google Scholar 

  21. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696–705.

    Article  PubMed  CAS  Google Scholar 

  22. Cobelli C, DallaMan C, Sparacino G, Magni L, De Nicolao G, Kovatchev BP. Diabetes: models, signals, and control. IEEE Rev Biomedical Eng. 2009;2:54–96.

    Article  Google Scholar 

  23. Meier JJ, Veldhuis JD, Butler PC. Pulsatile insulin secretion dictates systemic insulin delivery by regulating hepatic insulin extraction in humans. Diabetes. 2005;54:1649–56.

    Article  PubMed  CAS  Google Scholar 

  24. Sathananthan A, Man CD, Zinsmeister AR, Camilleri M, Rodeheffer RJ, Toffolo G, Cobelli C, Rizza RA, Vella A. A concerted decline in insulin secretion and action occurs across the spectrum of fasting and post-challenge glucose concentrations. Clin Endocrinol (Oxf), 2011.

  25. Basu A, Caumo A, Bettini F, Gelisio A, Alzaid A, Cobelli C, Rizza RA. Impaired basal glucose effectiveness in NIDDM: contribution of defects in glucose disappearance and production, measured using an optimized minimal model independent protocol. Diabetes. 1997;46:421–32.

    Article  PubMed  CAS  Google Scholar 

  26. Basu A, Rizza RA. Glucose effectiveness: measurement in diabetic and nondiabetic humans. Exp Clin Endocrinol Diabetes. 2001;109(Suppl 2):S157–65.

    Article  PubMed  CAS  Google Scholar 

  27. Delgado-Aros S, Cremonini F, Castillo JE, Chial HJ, Burton DD, Ferber I, Camilleri M. Independent influences of body mass and gastric volumes on satiation in humans. Gastroenterology. 2004;126:432–40.

    Article  PubMed  Google Scholar 

  28. Camilleri M. Integrated upper gastrointestinal response to food intake. Gastroenterology. 2006;131:640–58.

    Article  PubMed  CAS  Google Scholar 

  29. Kim DY, Camilleri M, Murray JA, Stephens DA, Levine JA, Burton DD. Is there a role for gastric accommodation and satiety in asymptomatic obese people? Obes Res. 2001;9:655–61.

    Article  PubMed  CAS  Google Scholar 

  30. McIntyre N, Holdsworth CD, Turner DS. New interpretation of oral glucose tolerance. Lancet. 1964;2:20–1.

    Article  PubMed  CAS  Google Scholar 

  31. Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia. 2011;54:10–8.

    Article  PubMed  CAS  Google Scholar 

  32. Fritsche A, Stefan N, Hardt E, Haring H, Stumvoll M. Characterisation of beta-cell dysfunction of impaired glucose tolerance: evidence for impairment of incretin-induced insulin secretion. Diabetologia. 2000;43:852–8.

    Article  PubMed  CAS  Google Scholar 

  33. Hinoi E, Gao N, Jung DY, Yadav V, Yoshizawa T, Myers MG Jr, Chua SC Jr, Kim JK, Kaestner KH, Karsenty G. The sympathetic tone mediates leptin’s inhibition of insulin secretion by modulating osteocalcin bioactivity. J Cell Biol. 2008;183:1235–42.

    Article  PubMed  CAS  Google Scholar 

  34. Ferron M, Wei J, Yoshizawa T, Del Fattore A, DePinho RA, Teti A, Ducy P, Karsenty G. Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell. 2010;142:296–308.

    Article  PubMed  CAS  Google Scholar 

  35. Engelke JA, Hale JE, Suttie JW, Price PA. Vitamin K-dependent carboxylase: utilization of decarboxylated bone Gla protein and matrix Gla protein as substrates. Biochim Biophys Acta. 1078;31–34:1991.

    Google Scholar 

  36. Fulzele K, Riddle RC, DiGirolamo DJ, Cao X, Wan C, Chen D, Faugere M-C, Aja S, Hussain MA, Bruning JC, Clemens TL. Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body composition. Cell. 2010;142:309–19.

    Article  PubMed  CAS  Google Scholar 

  37. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, Shen J, Vinson C, Rueger JM, Karsenty G. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell. 2000;100:197–207.

    Article  PubMed  CAS  Google Scholar 

  38. Binkley NC, Krueger DC, Engelke JA, Foley AL, Suttie JW. Vitamin K supplementation reduces serum concentrations of under-gamma-carboxylated osteocalcin in healthy young and elderly adults. Am J Clin Nutr. 2000;72:1523–8.

    PubMed  CAS  Google Scholar 

  39. Bach AU, Anderson SA, Foley AL, Williams EC, Suttie JW. Assessment of vitamin K status in human subjects administered “minidose” warfarin. Am J Clin Nutr. 1996;64:894–902.

    PubMed  CAS  Google Scholar 

  40. Kumar R, Binkley N, Vella A. Effect of phylloquinone supplementation on glucose homeostasis in humans. Am J Clin Nutr. 2010;92:1528–32.

    Article  PubMed  CAS  Google Scholar 

  41. Suttie JW, Hageman JM. Vitamin K-dependent carboxylase. Development of a peptide substrate. J Biol Chem. 1976;251:5827–30.

    PubMed  CAS  Google Scholar 

  42. Gravenstein KS, Napora JK, Short RG, Ramachandran R, Carlson OD, Metter EJ, Ferrucci L, Egan JM, Chia CW. Cross-sectional evidence of a signaling pathway from bone homeostasis to glucose metabolism. J Clin Endocrinol Metab. 2011;96:E884–90.

    Article  PubMed  CAS  Google Scholar 

  43. Fernandez-Real JM, Izquierdo M, Ortega F, Gorostiaga E, Gomez-Ambrosi J, Moreno-Navarrete JM, Fruhbeck G, Martinez C, Idoate F, Salvador J, Forga L, Ricart W, Ibanez J. The relationship of serum osteocalcin concentration to insulin secretion, sensitivity, and disposal with hypocaloric diet and resistance training. J Clin Endocrinol Metab. 2009;94:237–45.

    Article  PubMed  CAS  Google Scholar 

  44. Bao Y-Q, Zhou M, Zhou J, Lu W, Gao Y-C, Pan X-P, Tang J-L, Lu H-J, Jia W-P. Relationship between serum osteocalcin and glycaemic variability in Type 2 diabetes. Clin Exp Pharmacol Physiol. 2011;38:50–4.

    Article  PubMed  CAS  Google Scholar 

  45. Das SK, Sharma NK, Elbein SC. Analysis of osteocalcin as a candidate gene for type 2 diabetes (T2D) and intermediate traits in Caucasians and African Americans. Dis Markers. 2010;28:281–6.

    PubMed  Google Scholar 

  46. Stolerman ES, Florez JC. Genomics of type 2 diabetes mellitus: implications for the clinician. Nat Rev Endocrinol. 2009;5:429–36.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Supported by NIH grants DK78646 and DK82396 (to Adrian Vella) and AR058003 and AR060869 (to Rajiv Kumar) and a grant from the Ralph and Marion C. Falk Foundation (to Rajiv Kumar).

Author information

Authors and Affiliations

  1. Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA

    Adrian Vella & Rajiv Kumar

  2. Division of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA

    Adrian Vella

  3. Division of Nephrology and Hypertension, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA

    Rajiv Kumar

  4. Department of Biochemistry and Molecular Biology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA

    Rajiv Kumar

Authors
  1. Adrian Vella
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rajiv Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rajiv Kumar.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vella, A., Kumar, R. Osteocalcin and the Regulation of Glucose Metabolism. Clinic Rev Bone Miner Metab 11, 11–16 (2013). https://doi.org/10.1007/s12018-012-9126-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12018-012-9126-x

Keywords

Search

Navigation